Yuhan Corp
KRX:000100
Yuhan Corp
Net Income (Common)
Yuhan Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩69.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
₩240.7B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Net Income (Common)
₩59.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩121.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
18%
|
CAGR 10-Years
13%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
-₩10.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Net Income (Common)
₩16.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
81%
|
CAGR 10-Years
16%
|
|
Yuhan Corp
Glance View
In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.
See Also
What is Yuhan Corp's Net Income (Common)?
Net Income (Common)
69.6B
KRW
Based on the financial report for Dec 31, 2024, Yuhan Corp's Net Income (Common) amounts to 69.6B KRW.
What is Yuhan Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-2%
Over the last year, the Net Income (Common) growth was -48%. The average annual Net Income (Common) growth rates for Yuhan Corp have been -12% over the past three years , 12% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet